Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01839799 · ClinicalTrials.gov registry record · Phase 2
A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma
A Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT01839799: Completed Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT01839799 is a Phase 2 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01839799, a Phase 2 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
Determine the relapse-free survival of resected pancreatic cancer patients following two novel regimens with activity in advanced disease.
Primary Outcome
In this small trial we will regard a median progression-free survival of 20 months as indicative of potential therapeutic benefit meriting additional study.
Interventions
- RADIATION Chemoradiation
- DRUG Gemcitabine
- DRUG FOLFIRINOX
- DRUG Abraxane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2013-04 |
| Est. Completion | 2017-07 |
| Phase | Phase 2 |
What the finished NCT01839799 record still lists
NCT01839799 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 4 interventions - of which Chemoradiation is the first listed.
NCT01839799 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01839799 about?
NCT01839799 is a clinical study titled "A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma". Determine the relapse-free survival of resected pancreatic cancer patients following two novel regimens with activity in advanced disease.
What is the current status of trial NCT01839799?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2013-04. Estimated completion is 2017-07.
What interventions are being tested in trial NCT01839799?
The interventions under investigation include: Chemoradiation (RADIATION), Gemcitabine (DRUG), FOLFIRINOX (DRUG), Abraxane (DRUG).
Who is sponsoring clinical trial NCT01839799?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01839799's enrollment target sits among peer trials
32 1563rd of 2000 higher than 423 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia